Vivos Therapeutics, Inc. — Form 8-K
Filed September 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Baker Tilly US, LLP, Vivos's auditor, confirmed via letter dated September 30, 2026 that it agrees with statements made by the company regarding the auditor change disclosed in Item 4.01(a) of the Form 8-K. No specific reason for the auditor change, financial impact, or details of disagreements are provided in this exhibit.
Why this rating
Auditor change is routine disclosure; no dispute, restatement, or financial detail disclosed. Standard procedural filing.
Extracted items
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.